Faslodex: Help and Aid Against Breast Cancer

Faslodex, or fulvestrant, is a prescription medication used to treat hormone receptor-positive metastatic breast cancer in postmenopausal women. It works by binding to and degrading estrogen receptors, hindering cancer cell growth. Administered intramuscularly, Faslodex is often used when other hormonal treatments fail. Its unique receptor-degrading action makes it a valuable oncology therapy. Common side effects include injection site pain, nausea, and fatigue. Faslodex is integral to treatment plans aiming to prolong survival and improve quality of life in advanced breast cancer patients.

Faslodex

Faslodex, generically fulvestrant, treats hormone receptor-positive metastatic breast cancer in postmenopausal women post-failure of other anti-estrogen drugs. It acts by degrading estrogen receptors on cancer cells, reducing estrogen-induced cancer growth. Delivered intramuscularly, initially biweekly, then monthly, often in combination therapies, Faslodex enhances progression-free survival. Common side effects include injection pain and fatigue.

Select Wishlist

    Left Menu Icon
    Your Cart